Therapeutic Validation of GEF-H1 Using a De Novo Designed Inhibitor in Models of Retinal Disease. (2022)
Attributed to:
Regulation of RhoGTPase signalling at endothelial junctions and blood vessel integrity
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cells11111733
PubMed Identifier: 35681428
Publication URI: http://europepmc.org/abstract/MED/35681428
Type: Journal Article/Review
Volume: 11
Parent Publication: Cells
Issue: 11
ISSN: 2073-4409